Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments

被引：0

作者：

Nieto Barbero, Ma Asuncion ^{[1
]}

Javier Gonzalez-Gamiz, Francisco ^{[1
]}

Jesus Rodriguez-Nieto, Ma ^{[2
]}

Sanchez, Susana ^{[3
]}

Gaudo, Javier ^{[4
]}

Valenzuela, Claudia ^{[5
]}

Lopez-Muniz, Belen ^{[6
]}

Gomez-Carrera, Luis ^{[7
]}

Laporta, Rosalia ^{[8
]}

Casanova, Alvaro ^{[9
]}

Teresa Rio, Maria ^{[10
]}

Neumomadrid, Refipimad ^{[11
]}

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Fdn Jimenez Diaz, Madrid, Spain

[3] Hosp Univ Principe de Asturias, Alcaa De Henares, Spain

[4] Hosp Univ Ramon y Cajal, Madrid, Spain

[5] Hosp Univ Princesa, Madrid, Spain

[6] Hosp Univ Infanta Leonor, Madrid, Spain

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Puerta de Hierro, Majadahonda, Spain

[9] Hosp Univ Henares, Coslada, Spain

[10] Hosp Univ Getafe, Getafe, Spain

[11] Neumomadrid, Madrid, Spain

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

Idiopathic pulmonary fibrosis; Treatments; Comorbidities;

D O I：

10.1183/13993003.congress-2019.PA1301

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA1301

引用

页数：3

共 50 条

[41] Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, Huiping
Hui, Siu L.
Lee, Joyce S.
Zhang, Zuoyi
Boente, Ryan D.
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (10) : 1407 - 1415
[42] Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis
O'Mahony, A. T.
Waldron, M. G.
Henry, P. J.
Shet, S.
O'Regan, P. W.
Bennett, D. M.
Ryan, D. J.
Maher, M. M.
Henry, M. T.
CLINICAL RADIOLOGY, 2025, 81
[43] Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Nayci, Sibel
Polat, Demet
Ozgur, Eylem Sercan
Ozge, Cengiz
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[44] Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, Christopher S.
Nathan, Steven D.
LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 72 - 84
[45] Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Miia Kärkkäinen
Hannu-Pekka Kettunen
Hanna Nurmi
Tuomas Selander
Minna Purokivi
Riitta Kaarteenaho
Respiratory Research, 18
[46] Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, Michael
Ehlers-Tenenbaum, Svenja
Palmowski, Karin
Bruhwyler, Jacques
Oltmanns, Ute
Muley, Thomas
Heussel, Claus Peter
Warth, Arne
Kolb, Martin
Herth, Felix J. F.
PLOS ONE, 2016, 11 (03):
[47] Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Karkkainen, Miia
Kettunen, Hannu-Pekka
Nurmi, Hanna
Selander, Tuomas
Purokivi, Minna
Kaarteenaho, Riitta
RESPIRATORY RESEARCH, 2017, 18
[48] Persistence of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Pulmonary Fibrosis Foundation Patient Registry Study
Kulkarni, Tejaswini
Flaherty, Kevin
Gupta, Sachin
Tu, Yi-Hsuan
Case, Amy Hajari
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2025, 22 (01) : 165 - 168
[49] Existing and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, Lykourgos
Papiris, Spyridon
Bouros, Demosthenes
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (03) : 229 - 239
[50] What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Moua, Teng
Baqir, Misbah
Ryu, Jay H.
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (21)

← 1 2 3 4 5 →